SNDT WOMEN'S UNIVERSITY
BMK Knowledge Resource Centre
Vithaldas Vidyavihar, Juhu Tara Road,
Santacruz (West) Mumbai - 400049
METHOD DEVELOPMENT AND VALIDATION FOR QUANTIFICATION OF IMATINIB MESYLATE SPIKED IN VITRO SALIVA BY LC-MS/MS (Record no. 131175)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01998nam a2200157 4500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 250220b |||||||| |||| 00| 0 eng d |
| 082 ## - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Item number | P.46-56 |
| 100 ## - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Swetha Sri Remidicherla |
| 245 ## - TITLE STATEMENT | |
| Title | METHOD DEVELOPMENT AND VALIDATION FOR QUANTIFICATION OF IMATINIB MESYLATE SPIKED IN VITRO SALIVA BY LC-MS/MS |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | P.46-56 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. biblio.abstract | A novel, sensible, rapid, reliable and economical analytical hyphenated LC-MS/MS method has been developed as a key for the safety surveillance in chronic leukemia patients, and as a part of therapeutic drug monitoring of imatinib mesylate in human saliva. Imatinib mesylate or imatinib methane sulfonate is a tyrosine kinase inhibitor, apoptosis inducer and also known to be an anticoronaviral agent. Imatinib mesylate is a monomesylate salt of imatinib used for the treatment of gastrointestinal tumors and chronic myelogenous leukemia, and also in other complex malignancies. The lmax of imatinib mesylate was observed at 258 nm by UV spectrometry, establishing a very good linearity along with sensitivity. The detection limit (LOD) =0.2925 µg mL-1 and quantitation limit (LOQ)= 0.8977 µg mL- ¹ were obtained from the linear concentrations taken in the range of 2-12 µg mL-1. The correlation coefficient (r2 ) found was 0.999. The method validation parameters according to ICH Q2 (R1) were performed. The developed method described here, UPLC-MS/MS, was found to be novel, sensitive and rapid with improved results when successfully tested for human saliva samples without significant differences in the steady state imatinib mesylate concentrations. Current method could overcome the safety issues during therapeutic drug monitoring and pharmacokinetic behavior of the drug when tested clinically. |
| 654 ## - SUBJECT ADDED ENTRY--FACETED TOPICAL TERMS | |
| Subject | <a href="Imatinib mesylate ">Imatinib mesylate </a> |
| -- | <a href="LOD">LOD</a> |
| -- | <a href="LOQ">LOQ</a> |
| -- | <a href="ICH Q2 (R1)">ICH Q2 (R1)</a> |
| -- | <a href="LC-MS/MS">LC-MS/MS</a> |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Guntupalli Chakravarthi |
| 773 0# - HOST ITEM ENTRY | |
| Host Biblionumber | 125265 |
| Host Itemnumber | 109669 |
| Place, publisher, and date of publication | Mumbai Indian Drugs Manufacturer's Association |
| Title | Indian Drugs |
| International Standard Serial Number | 0019-462X |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Koha item type | Journal Article |
No items available.